重组人脑钠肽间歇性给药联合左西孟旦治疗难治性心力衰竭的效果观察  

Observation of the effect of intermittent administration of recombinant human brain natriuretic peptide combined with levosimendan in the treatment of refractory heart failure

作　　者：仝峰[1] 杨琴[1] 袁玲霞[1] 乔雯雯[1] 陈建涛[1] TONG Feng;YANG Qin;YUAN Lingxia;QIAO Wenwen;CHEN Jiantao(Department of Cardiology,Jiaozuo Second People’s Hospital,Jiaozuo 450000,China)

机构地区：[1]河南省焦作市第二人民医院心内科

出　　处：《右江医学》2020年第1期66-69,共4页Chinese Youjiang Medical Journal

摘　　要：目的观察重组人脑钠肽间歇性给药联合左西孟旦治疗难治性心力衰竭的临床效果。方法选择2016年6月~2018年1月收治的难治性心力衰竭患者作为研究对象(80例),根据随机数字表将纳入的研究对象分为两组。所有患者均给予常规抗心衰治疗,在此基础上,观察组40例患者采用重组人脑钠肽间歇性给药联合左西孟旦治疗;对照组40例患者采用重组人脑钠肽持续给药联合左西孟旦治疗。结果观察组显效33例、有效5例、无效2例,与对照组(显效35例、有效3例、无效2例)比较,差异无统计学意义(P>0.05)。观察组治疗前各指标与对照组比较,差异无统计学意义(P>0.05);治疗后心率、平均动脉压、左心室舒张末期内径(LVEDD)、血清N末端脑钠肽前体(NT-proBNP)下降,尿量及左心室射血分数(LVEF)升高,与对照组治疗后比较差异无统计学意义(P>0.05)。结论在重组人脑钠肽联合左西孟旦治疗难治性心力衰竭中,重组人脑钠肽间歇性给药可代替持续给药。Objective To observe the clinical effect of intermittent administration of recombinant human brain natriuretic peptide combined with levosimendan in the treatment of refractory heart failure.Methods 80 patients with refractory heart failure admitted to hospital from June 2016 to January 2018 were selected as study subjects.They were divided into two groups according to random number table.All patients were given routine anti-heart failure treatment.On this basis,40 patients in observation group were treated with intermittent administration of recombinant human brain natriuretic peptide combined with levosimendan,while 40 patients in control group were treated with continuous administration of recombinant human brain natriuretic peptide combined with levosimendan.Results 33 cases were markedly effective,5 cases were effective and 2 cases were ineffective in the observation group.Compared with the control group(35 cases were markedly effective,3 cases were effective and 2 cases were ineffective),difference was no statistically significant(P>0.05).There was no significant difference in each index between the observation group and the control group before treatment(P>0.05).After treatment,heart rate,mean arterial pressure,left ventricular end-diastolic diameter(LVEDD) and serum N-terminal pro-B-type natriuretic peptide(NT-proBNP) decreased in the observation group,while urine volume and left ventricular ejection fraction(LVEF) increased,but there were no statistically significant differences while comparing with those in the control group(P>0.05).Conclusion Intermittent administration of recombinant human brain natriuretic peptide can replace continuous administration in the treatment of refractory heart failure by recombinant human brain natriuretic peptide combined with levosimendan.

关 键 词：重组人脑钠肽 间歇性给药 左西孟旦 难治性心力衰竭 

分 类 号：R541.61[医药卫生—心血管疾病]